A key focus for the Oxford Consortium for Single-Cell Biology is to apply newly developed single-cell techniques to functional genomics. As part of this, the consortium is hosting Dave Ruff to help advance gene editing approaches at the single-cell level. Dave is a thought leader in the development of single-cell methods and will be presenting both the latest technologies and where he thinks the breakthroughs in single-cell systems biology over the next few years will be.
Before joining Fluidigm in early 2013, Dave spent 17 years innovating qPCR and next-generation sequencing (NGS) technologies at Applied Biosystems/Life Technologies. He has been a lead investigator in the development of qPCR assays and chemistry, multiplex preamplification, protein quantification, NGS library preparation, sample-to-answer workflows, single-cell analysis, and nucleic acid sample-preparation processes. Prior to Applied Biosystems, Dave served as a research scientist at several early-stage biotechnology companies in California, including five years at Amgen. He received his academic instruction in biochemistry and molecular biology at the University of California, Riverside and California Institute of Technology. Dave is currently active in advancing single-cell research topics centered around epigenetics, multimodal quantification and genome editing. He also serves on the editorial board of the Elsevier Journal Biomolecular Detection and Quantification.